Gemcitabine/Nab-Paclitaxel Until Progression or Alternating With FOLFIRI.3 for Metastatic Pancreatic Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gemcitabine Plus Nab-Paclitaxel Until Progression or Alternating With FOLFIRI.3, as First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 Randomised Phase II Study (FIRGEMAX)
Eur. J. Cancer 2020 Jul 02;136(xx)25-34, Y Rinaldi, AL Pointet, F Khemissa Akouz, K Le Malicot, B Wahiba, S Louafi, A Gratet, L Miglianico, H Laharie, K Bouhier Leporrier, A Thirot Bidault, P Texereau, R Coriat, E Terrebonne, MC Gouttebel, D Malka, JB Bachet, C Lepage, J TaiebFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.